Dr. Tessa Sinnige
The molecular mechanisms of protein aggregation in a living organism
A wide variety of human diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and diabetes type II, are associated with the deposition of insoluble protein aggregates containing amyloid fibrils. The conversion of monomeric protein into amyloid fibrils has been studied extensively in test tube reactions, but how protein aggregation takes place in living cells and organisms remains poorly understood. A key difference between in vitro and in vivo conditions is that cells and organisms have evolved intricate networks for protein quality control. These include molecular chaperones that aid correct protein folding, and degradation machineries that eliminate aberrant protein species. Furthermore, amyloid formation in a biological context is affected by the presence of other cellular components, including membranes. The presence of membranes promotes amyloid formation of several disease-associated proteins, and membranes are also thought to be targeted by pore-forming aggregate species leading to toxicity.
In our lab, we use the roundworm Caenorhabditis elegans as a model organism to study disease-related protein aggregation in vivo. C. elegans is relatively short-lived and optically transparent, allowing us to track the aggregation of fluorescently labelled proteins across its lifespan. Using a combination of different microscopy techniques, genetics, biochemistry, structural biology, and mathematical modelling, we aim to obtain a molecular and quantitative understanding of protein aggregation and its relation to disease.
Using fluorescence lifetime imaging (FLIM), amyloid formation can be visualised in living C. elegans. The formation of amyloid-like inclusions by YFP-tagged alpha-synuclein and polyglutamine (40 glutamines, Q40) is associated with a reduction in the fluorescence lifetime. Laine, Sinnige et al. (2019) ACS Chem Bio 14(7), 1628-1636.
Selected Publications
- M Joshi, S van Falier, T Sinnige (2025) Human tau compromises neuronal structural integrity in C. elegans promoted by age, stress and phosphorylation. bioRxiv, 2025.08. 01.668095
- M Akdag, S Ferreira, R Menezes, T Sinnige (2025) Urolithin B reduces the aggregate load of islet amyloid polypeptide in Caenorhabditis elegans. bioRxiv, 2025.07. 01.662492
- M. Akdag, V. van Schijndel, T. Sinnige (2024) Islet amyloid polypeptide tagged with green fluorescent protein localises to mitochondria and forms filamentous aggregates in Caenorhabditis elegans. Biophysical Chemistry 307, 107180
- B.O.W. Elenbaas, S.M. Kremsreiter, L. Khemtemourian, J.A. Killian, T. Sinnige (2023) Fibril elongation by human islet amyloid polypeptide is the main event linking aggregation to membrane damage. BBA Advances 3,100083
- B.O.W. Elenbaas, L. Khemtemourian, J.A. Killian, T. Sinnige (2022) Membrane-catalyzed aggregation of islet amyloid polypeptide is dominated by secondary nucleation. Biochemistry 61, 1465-1472
- T. Sinnige (2022) Molecular mechanisms of amyloid formation in living systems. Chem. Sci. 13, 7080 – 7097
- J. Molenkamp, A. den Outer, V. van Schijndel, T. Sinnige (2021) Monitoring protein aggregation kinetics in vivo using automated inclusion counting in Caenorhabditis elegans. J. Vis. Exp. 178, e63365
- T. Sinnige, G. Meisl, T.C.T. Michaels, M. Vendruscolo, T.P.J. Knowles, R.I. Morimoto (2021) Kinetic analysis reveals reveals that independent nucleation events determine the progression of polyglutamine aggregation in C. elegans. Proc. Natl. Acad. Sci. U.S.A 118(11) e2021888118